BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 07, 2009
 |  BioCentury  |  Strategy

Meeting the Biota Quota

Biota Holdings Ltd.'s acquisition of MaxThera Inc. and Prolysis Ltd. fills some holes in its pipeline, which should help it achieve its long-term goal of having two or three out-licensed, royalty-generating compounds on the market at all times.

Biota receives royalties from GlaxoSmithKline plc for sales of Relenza zanamivir, an inhaled neuraminidase inhibitor marketed to prevent and treat influenza infection. In its FY09 ended June 30, Biota received A$45 million ($36.5 million) in Relenza royalties, up from A$20.5 million ($19.6 million) in FY08.

The Relenza royalties made up the lion's share of Biota's A$83.3 million ($67.6 million) in total revenues, and the company expects the royalties to increase as governments stockpile the drug in response to the swine influenza A (H1N1) pandemic. Indeed, GSK said it intended to more than triple its Relenza manufacturing capacity from 60 to 190 million courses by year end.

Relenza will go off patent in the U.S. and in Europe in 2014 and in Japan in 2019. The next product that could generate royalties for Biota is laninamivir,...

Read the full 867 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >